A single intranasal dose of a short-acting psychedelic cut treatment-resistant depression scores in a randomized trial
Psychedelic medicine's biggest logistical problem has always been the clock โ psilocybin sessions run six to eight hours, which is a hard sell for overstretched clinics.
A new randomized trial just tested whether a drug that compresses that window down to minutes can still move the needle on treatment-resistant depression.
A Brief Psychedelic Experience, One Dose, Published in JAMA ๐งช
- Intranasal mebufotenin (5-MeO-DMT) โ a compound associated with short psychedelic experiences โ was tested in a randomized clinical trial against treatment-resistant depression, published in JAMA.
- The appeal is structural: unlike psilocybin or LSD, which require hours of in-clinic monitoring, mebufotenin's psychedelic window is brief, potentially cutting the session footprint dramatically.
- The study targets one of psychiatry's hardest problems โ patients who haven't responded to existing antidepressants โ with a single administration design.
Why it matters: If the efficacy signal holds, the logistics argument alone reshapes how psychedelic-assisted therapy could be deployed at scale.
Key Findings
Psilocybin and Psychosis: 40 Years of Data, One Honest Takeaway ๐
- A systematic review covering 1984โ2025 mapped the relationship between classical psychedelics โ LSD, psilocybin, ayahuasca, and mescaline โ and psychotic symptoms.
- The review aimed to give clinicians and policymakers a framework for identifying who is most at risk, synthesizing evidence on prevalence, risk factors, and clinical characteristics across four decades of studies.
Mushrooms Invented Psilocybin Twice โ Independently ๐ฌ
- A review of psilocybin's biosynthetic pathway found that mushrooms evolved the ability to produce the compound on two separate, independent occasions โ using genes and enzymes that are only distantly related or unrelated altogether.
- The review also maps how psilocybin can be produced biocatalytically in lab settings, either in test tubes or in engineered organisms, which matters for pharmaceutical manufacturing.
Psilocybin vs. Escitalopram: Does Sex Change the Outcome? โโ
- A Bayesian secondary analysis of a psilocybin-versus-escitalopram trial examined whether treatment outcomes differed by sex โ a question rarely asked in psychedelic research, where females are often underrepresented.
- Major depressive disorder already shows marked sex differences in prevalence and symptom patterns, making the gap in sex-stratified trial data a meaningful blind spot.
A Ketamine Cousin With Fewer Side Effects โ In Mice โ๏ธ
- Researchers identified 3C-DCK, a rationally designed ketamine derivative, that produced rapid antidepressant-like effects in chronically stressed mice lasting up to 72 hours after a single 2 mg/kg dose โ longer than ketamine itself.
- The mechanism runs through adenosine signaling in the prefrontal cortex rather than the pathways associated with ketamine's dissociative and abuse-related side effects. No hyperlocomotion or movement problems were observed in the animal model.
Ketamine in Adolescence Didn't Raise Addiction Risk Later โ In Rats ๐
- Male and female rats given a therapeutic dose of ketamine (10 mg/kg daily for 7 days) during adolescence showed no increased voluntary alcohol consumption or cocaine reward behavior in adulthood compared to saline controls.
- The dose was selected specifically because it produces antidepressant-like effects in adolescent rats, making it a relevant proxy for the clinical question of whether treating teenage depression with ketamine carries long-term addiction risk.
Ketamine Reshapes Brain Entropy in Treatment-Resistant Depression ๐ง
- Data from two neuroimaging clinical trials found that low-dose ketamine modulated brain entropy โ a measure of signal complexity โ in regions linked to mood regulation, reward, and motivation in patients with treatment-resistant depression.
- Prior work had shown entropy reductions in those regions in depressed patients; this study examined whether ketamine shifts that pattern.
Implications
The week's evidence pulls in one coherent direction: faster, cleaner, more targeted tools for depression that hasn't responded to standard treatment. The unresolved tension is translation โ adenosine derivatives and brain entropy findings come from animals and small imaging studies, while the mebufotenin trial's durability beyond a single dose remains an open question.
Studies in this issue
Primary sources used for this newsletter.
- Single Dose of the Psychedelic Mebufotenin by Nose for Hard-to-Treat Depression: A Randomized Clinical Trialmain storyJAMA2026-10-26PMID 42931733
- The genes and enzymes involved in making psilocybinkey findingMicrobiology and molecular biology reviews : MMBR2026-10-27PMID 42937360
- Does ketamine treatment in adolescence affect adult risk of drug abuse in rats?key findingPsychopharmacology2026-10-26PMID 42928272
- A ketamine-related drug may have stronger antidepressant effects through adenosine signalingkey findingScience China. Life sciences2026-10-26PMID 42932044
- Psychedelics and psychosis: A review of recent studies from 1984 to 2025key findingJournal of psychopharmacology (Oxford, England)2026-10-27PMID 42937077
- Differences between men and women in responses to psilocybin or escitalopramkey findingPsychopharmacology2026-10-26PMID 42931904
- Low-dose ketamine may change brain signal complexity in hard-to-treat depressionkey findingJournal of affective disorders2026-10-26PMID 42933579
Continue reading
All Psychedelic Science issuesGet the next Psychedelic Science issue
Seven papers, once a week. Free.